At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful ...

Novavax (NASDAQ:NVAX) shares climbed about 5% on Tuesday after the biotech group disclosed a non-exclusive licensing ...

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...

As its lead candidate advances into a late-stage trial for pulmonary arterial hypertension (PAH), Inhibikase Therapeutics has picked up a commercial leader with plenty of experience in the PAH space.

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

ZURICH (MarketWatch) -- Swiss biotechnology company Cytos Biotechnology Ltd (CYTN.EB) said Monday Pfizer Inc. PFE has taken commercial licenses for specified vaccines based on Cytos' immunodrug ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...